Coultreon
Innovative immunology drug developer
About
Founded in 2025 and rebranded from Onco3R Therapeutics, Coultreon Biopharma focuses on developing immunology therapies by rescuing and advancing promising drug candidates licensed from Galapagos, including their SIK3 inhibitor program. The company operates a biotech model, supported by major pharma investors, to advance oral pill therapeutics that mimic injectable biologics, targeting alternative immune pathways for inflammatory diseases. Its business model leverages strategic financing and partnerships to accelerate clinical testing and pipeline expansion.
Products
-
COL-5671
— Oral selective SIK3 inhibitor restoring immune balance by suppressing pro-inflammatory cytokines and promoting immune resolution.
Customer sectors: immunologists, pharmaceutical developers, clinical researchers
-
SM Immunology
— Undisclosed immunology therapy targeting multiple inflammatory pathways to treat chronic inflammatory diseases.
Customer sectors: immunologists, pharmaceutical developers
-
SM Metabolic
— Undisclosed metabolic disease therapy designed to address chronic metabolic disorders.
Customer sectors: endocrinologists, pharmaceutical developers
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Coultreon — available to members.
